Francisco Javier Álvarez-Gutiérrez , Marina Blanco Aparicio , Francisco Casas Maldonado , Vicente Plaza , Gregorio Soto Campos , Francisco Javier González-Barcala , Carlos Almonacid , Ebymar Arismendi , Carlos Cabrera , Roberto Cabestre García , José Ángel Carretero , Manuel Castilla Martínez , José Antonio Castillo Vizuete , Carolina Cisneros Serrano , Álvaro Gimeno Díaz de Atauri , David Diaz Pérez , Christian Domingo Ribas , Juan Luis García Rivero , Alejandro López Neyra , Eva Martínez Moragón , José Valverde Molina
{"title":"严重哮喘的共识文件。2025年更新","authors":"Francisco Javier Álvarez-Gutiérrez , Marina Blanco Aparicio , Francisco Casas Maldonado , Vicente Plaza , Gregorio Soto Campos , Francisco Javier González-Barcala , Carlos Almonacid , Ebymar Arismendi , Carlos Cabrera , Roberto Cabestre García , José Ángel Carretero , Manuel Castilla Martínez , José Antonio Castillo Vizuete , Carolina Cisneros Serrano , Álvaro Gimeno Díaz de Atauri , David Diaz Pérez , Christian Domingo Ribas , Juan Luis García Rivero , Alejandro López Neyra , Eva Martínez Moragón , José Valverde Molina","doi":"10.1016/j.opresp.2025.100486","DOIUrl":null,"url":null,"abstract":"<div><div>Severe asthma is a heterogeneous syndrome with several clinical variants and often represents a complex disease requiring a specialized and multidisciplinary approach, as well as the use of multiple drugs. The prevalence of severe asthma varies from one country to another, and it is estimated that 50% of these patients present a poor control of their disease. For the best management of the patient, it is necessary to have a correct diagnosis, an adequate follow-up and undoubtedly to offer the best available treatment, including biologic treatments with monoclonal antibodies. With this objective, this consensus process was born, which began in its first version in 2018, whose goal is to offer the patient the best possible management of their disease to minimize their symptomatology. For this 2025 consensus update, a literature review was conducted by the authors, and new sections of how to treat asthma comorbidities or pediatric asthma were added, as a paragraph about monoclonal antibody switch. Subsequently, through a two-round interactive Delphi process, a broad panel of asthma experts from SEPAR and the regional pulmonology societies proposed the recommendations and conclusions contained in this document.</div></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"7 4","pages":"Article 100486"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Documento de consenso de asma grave. Actualización 2025\",\"authors\":\"Francisco Javier Álvarez-Gutiérrez , Marina Blanco Aparicio , Francisco Casas Maldonado , Vicente Plaza , Gregorio Soto Campos , Francisco Javier González-Barcala , Carlos Almonacid , Ebymar Arismendi , Carlos Cabrera , Roberto Cabestre García , José Ángel Carretero , Manuel Castilla Martínez , José Antonio Castillo Vizuete , Carolina Cisneros Serrano , Álvaro Gimeno Díaz de Atauri , David Diaz Pérez , Christian Domingo Ribas , Juan Luis García Rivero , Alejandro López Neyra , Eva Martínez Moragón , José Valverde Molina\",\"doi\":\"10.1016/j.opresp.2025.100486\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Severe asthma is a heterogeneous syndrome with several clinical variants and often represents a complex disease requiring a specialized and multidisciplinary approach, as well as the use of multiple drugs. The prevalence of severe asthma varies from one country to another, and it is estimated that 50% of these patients present a poor control of their disease. For the best management of the patient, it is necessary to have a correct diagnosis, an adequate follow-up and undoubtedly to offer the best available treatment, including biologic treatments with monoclonal antibodies. With this objective, this consensus process was born, which began in its first version in 2018, whose goal is to offer the patient the best possible management of their disease to minimize their symptomatology. For this 2025 consensus update, a literature review was conducted by the authors, and new sections of how to treat asthma comorbidities or pediatric asthma were added, as a paragraph about monoclonal antibody switch. Subsequently, through a two-round interactive Delphi process, a broad panel of asthma experts from SEPAR and the regional pulmonology societies proposed the recommendations and conclusions contained in this document.</div></div>\",\"PeriodicalId\":34317,\"journal\":{\"name\":\"Open Respiratory Archives\",\"volume\":\"7 4\",\"pages\":\"Article 100486\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Respiratory Archives\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2659663625000906\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Respiratory Archives","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2659663625000906","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Documento de consenso de asma grave. Actualización 2025
Severe asthma is a heterogeneous syndrome with several clinical variants and often represents a complex disease requiring a specialized and multidisciplinary approach, as well as the use of multiple drugs. The prevalence of severe asthma varies from one country to another, and it is estimated that 50% of these patients present a poor control of their disease. For the best management of the patient, it is necessary to have a correct diagnosis, an adequate follow-up and undoubtedly to offer the best available treatment, including biologic treatments with monoclonal antibodies. With this objective, this consensus process was born, which began in its first version in 2018, whose goal is to offer the patient the best possible management of their disease to minimize their symptomatology. For this 2025 consensus update, a literature review was conducted by the authors, and new sections of how to treat asthma comorbidities or pediatric asthma were added, as a paragraph about monoclonal antibody switch. Subsequently, through a two-round interactive Delphi process, a broad panel of asthma experts from SEPAR and the regional pulmonology societies proposed the recommendations and conclusions contained in this document.